Document is current

Article History

Received: 27 September 2022

Accepted: 3 March 2023

First Online: 16 March 2023

Declarations

:

: Ethics approval was obtained from NORC at the University of Chicago Institutional Review Board (IRB00000967; Protocol #20.08.21). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Participants provided consent prior to beginning the survey.

: Not applicable. Data are only shared in aggregate form and contain no information on any individual patient. Participants were notified on the consent form: If there are any publications or presentations resulting from this research, no personally identifiable information will be shared.

: The authors report the following conflicts of interest. Institutional research support was granted to the Cancer Support Community and not individual study authors: Fortune: Institutional research funding from: AbbVie, Amgen Oncology, AstraZeneca, Astellas Pharma, Bristol Myers Squibb, Genentech, Gilead Sciences, Lilly Oncology, Merck & Co, Inc, Sumimoto Dainippon Pharma Co, Takeda Oncology. Zaleta: Institutional research funding from: Astellas Pharma, Gilead Sciences, Novartis, Pfizer Oncology, Seattle Genetics. Morris: None to disclose.